Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 open-label, dose-finding study of intravenous Ganaxolone in refractory status epilepticus patients

Next Previous
X
Search
Trial Profile

A Phase 2 open-label, dose-finding study of intravenous Ganaxolone in refractory status epilepticus patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Status epilepticus
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 24 Jun 2022 Results assessing the appropriate dosing for IV ganaxolone in RSE and obtain a preliminary assessment of efficacy and safety published in the Epilepsia
    • 09 Nov 2021 According to an Marinus Pharmaceuticals media release, data from this trial were presented during Neurocritical Care Society Annual Meeting in October.
    • 01 Sep 2021 Results assessing efficacy and safety of intravenous Ganaxolone in refractory status epilepticus patients, presented at the 34th International Epilepsy Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top